Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
Date:7/2/2012

lar study conducted by Celator in newly diagnosed elderly patients with secondary AML supported the initiation of the current Phase 3 program. LLS's TAP supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers. 

"This is not only welcome funding but also an important vote of confidence in the potential of CPX-351 to improve outcomes for patients with AML from an organization devoted to that goal," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "Our new agreement extends what has already been a very productive collaboration and we look forward to the day when these efforts  culminate in making a much-needed new treatment option available to patients with AML at large."

About CPX-351
CPX-351 represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the FDA for the treatment of AML. CPX-351 is in late-stage clinical development for the treatment of AML. Celator has completed a successful randomized, phase 2 study comparing CPX-351 to the standard "7+3" regimen of cytarabine:daunorubicin in patients 60 years of age up to and including 75 years of age with newly diagnosed AML and has also completed a randomized, phase 2 study of CPX-351 versus intensive salvage therapy in patients 18 years of age up to and including 65 years of age with AML in first relapse. The second study was supported by the original LLS TAP funding.

About Acute Myeloid Leukemia (AML)
The LLS defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow.  According to LLS, in 2012 approximately 12,950 ne
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
2. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
8. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/17/2014)... New York, NY (PRWEB) September 17, 2014 ... morcellators ( http://www.drugbot.com/morcellator/ ) in laparoscopic hysterectomies and other ... LLP reports. According to figures posted on Change.org, at ... September 17th. * , According to a recent report ... one year ago by Dr. Hooman Noorchashm, after his ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Leading ... announce the launch of its new vegan and gluten-free ... extremely effective and provided the results skincare testers were ... create a gentle yet active mask that provided results, ... Louise.” , This Sugar Cane Fruit Mask combines Willow ...
(Date:9/17/2014)... Cadiz Laser Spa offers the ... to clients throughout Central Texas. The newest addition ... Induction Therapy. Using the revolutionary Rejuvapen micro-needling device ... clients correct a wide variety of skin issues. ... Cadiz Laser Spa is currently offering a special ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 17, 2014 ... grant of $50,000 to the National Children’s Oral Health ... and education through NCOHF’s Orange County Oral Health Zone ... Health Zone Program is engaging a range of local ... breaking the cycle of severe tooth decay and its ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... (Pink Sheets: SNDY) is pleased to announce that ... was featured in the "Cover Products" section ... issue. The article focused on the MammoView(TM),s functionality ... in the mammary ducts.The MammoView(TM) product line employs ...
... Together Extensive State/Local Resources and Makes Medical History ... solution for families, consumers and professionals concerned with ... to all New Yorkers. The New York ... www.nycnetworkofcare.org ) is an online clearinghouse that provides ...
... Medicare Reimbursement will have Significant Impact on the ... Mass., Feb. 19 Millennium Research Group (MRG) ... for Urological Devices 2008 report to reflect ... Due mainly to a favorable upgrade in Medicare ...
... Top 100 Has Placed McLaren In Top 25 Nationwide Since ... The SDI Top 100, an annual list that ranks the ... has ranked Flint-based McLaren Health Care the top-rated health system ... the nation, placing it 16th on this year,s list.McLaren has ...
... - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) ... the fourth quarter ending December 31, 2008 and full year ... specified otherwise, all amounts are in U.S. dollars and in ... for us as we concluded a series of corporate development ...
... Fla., Feb. 19 Smith & Nephew,s Advanced Wound ... announced that the United States Patent and Trademark Office ... negative pressure wound therapy (NPWT) patents during re-examination of ... Patent Office found that prior art showed that almost ...
Cached Medicine News:Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 2Health News:NAMI-NYC Metro Gives New Yorkers the Most Comprehensive Mental Health Web Site in Effort to Help Transform Care 3Health News:Intermittent Catheter Market to Surpass 40% CAGR Between 2008 and 2012 2Health News:National Health Care List Ranks McLaren Health Care Top in Michigan; 16th in Nation 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19Health News:United States Patent Office Rejects KCI's Patents 2Health News:United States Patent Office Rejects KCI's Patents 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: